Definitive Analysis
Financial Statements
Periods / Units
Fundamentals
Valuations
Miscellaneous
Analysis Mode
Full Access
See Pricing Start Trial
Multiples Valuation: Eli Lilly and Company

Eli Lilly and Company (LLY)

Industry: Drug Manufacturers - General Model: Peers Multiples Valuation

Valuation Snapshot

Winsorized Fair Value
Range (Low - High) $211.74 — $351.68
Selected (Average) $290.49
Upside to Live -72.02%
Full Range Fair Value
Range (Low - High) $224.60 — $397.09
Selected (Average) $316.80
Upside to Live -69.49%
Live Price $1,038.40

Industry Peers Data

TickerRankNameRev TTM (M) Trailing P/EForward P/ETrailing EV/EBITDAForward EV/EBITDATrailing EV/EBITForward EV/EBIT
0QQ6.L 1 Roche Holding AG 133,599 12.69 13.18 7.79 8.16 11.35 7.65
JNJ 2 Johnson & Johnson 92,149 17.56 16.24 10.85 10.01 15.12 17.25
AZN.L 3 AstraZeneca PLC 78,284 22.65 17.30 12.21 10.26 16.83 14.80
NOVN.SW 4 Novartis AG 70,873 17.01 14.77 11.70 10.99 14.85 13.42
0QAH.L 5 Merck & Co., Inc. 64,235 11.01 9.96 8.45 7.62 7.70 8.66
PFE 6 Pfizer Inc. 62,785 13.81 13.24 9.26 8.18 13.80 10.06
ABBV 7 AbbVie Inc. 59,644 171.38 214.67 37.21 38.60 24.20 35.59
LLY 8 Eli Lilly and Comp 59,420 37.17 29.27 28.35 22.56 23.19 20.72
SNW.DE 9 Sanofi 53,933 10.84 11.25 8.80 8.50 7.43 13.56
BAYN.DE 10 Bayer AG 53,857 - - 10.08 10.08 - 11.54
BMY 11 Bristol-Myers Squi 48,034 15.22 15.22 8.54 8.40 8.74 7.17
CELG-RI 12 Bristol-Myers Squi 48,034 0.01 0.01 2.37 2.33 2.30 1.92
GS7.DE 13 GSK plc 47,231 11.06 9.42 7.80 7.04 15.37 10.68
AMGN 14 Amgen Inc. 35,959 21.67 21.88 11.91 11.33 19.49 23.01
GILD 15 Gilead Sciences, I 29,086 17.01 11.74 9.61 7.56 9.88 9.41
4578.T 16 Otsuka Holdings Co 15,536 9.24 7.36 6.89 6.01 8.28 8.37

Implied Valuation Analysis

Line Item Trailing P/EForward P/ETrailing EV/EBITDAForward EV/EBITDATrailing EV/EBITForward EV/EBIT
Winsorized Median Multiple13.2512.468.808.1810.6110.06
Full Range Median Multiple14.5113.219.268.4012.5810.68
Industry Multiple25.0826.8710.9010.3412.5212.87
Market Implied Multiple50.5839.8338.1130.3431.1827.86
Company (LLY) Multiple37.1729.2728.3522.5623.1920.72
(*) Net Income / EBITDA / Revenue18,41223,38425,29731,77730,92234,601
Winsorized Enterprise ValueN/AN/A222,629259,909328,192348,132
Full Range Median Enterprise ValueN/AN/A234,154266,857388,862369,691
(-) Net Debt32,71532,71532,71532,71532,71532,715
Winsorized Equity Value243,953291,311189,914227,194295,478315,418
Full Range Median Equity Value267,211308,909201,440234,143356,147336,977
(/) Shares Outstanding897897897897897897
Winsorized Fair Value$272.00$324.80$211.74$253.31$329.44$351.68
Full Range Median Fair Value$297.93$344.42$224.60$261.06$397.09$375.71
Current Price$1,038.40$1,038.40$1,038.40$1,038.40$1,038.40$1,038.40
Upside / Downside-73.81%-68.72%-79.61%-75.61%-68.27%-66.13%
Safety Margin30.0%30.0%30.0%30.0%30.0%30.0%
Buy Price$190.40$227.36$148.22$177.32$230.61$246.17
Buy / Don't BuyDon’t BuyDon’t BuyDon’t BuyDon’t BuyDon’t BuyDon’t Buy